Finance

Lists
Why is 603259 down 6,60%?
Dive Deeper
603259:SHA
WuXi AppTec Co Ltd
144,30 CN¥
-6,60%
(-10,20) 1D
16-окт., 15:00:01 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603259...
Open
156,94 CN¥
High
159,92 CN¥
Low
139,05 CN¥
Mkt. cap
447,48 млд
Avg. vol.
34,02 млн
Volume
83,61 млн
Dividend
1,45%
Quarterly dividend
0,52 CN¥
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
19,63
52-wk high
173,60 CN¥
52-wk low
87,09 CN¥
EPS
7,35 CN¥
Shares outstanding
1,05 млд
No. of employees
36 миң
Open
156,94 CN¥
High
159,92 CN¥
Low
139,05 CN¥
Mkt. cap
447,48 млд
Avg. vol.
34,02 млн
Volume
83,61 млн
Dividend
1,45%
Quarterly dividend
0,52 CN¥
Ex-dividend date
2026-ж., 4-сен.
P/E ratio
19,63
52-wk high
173,60 CN¥
52-wk low
87,09 CN¥
EPS
7,35 CN¥
Shares outstanding
1,05 млд
No. of employees
36 миң
News stories
From web sources and news partners
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Co Ltd
CEOSteve Yang | Ge Li
Employees35,6 миң
Founded2000-ж., 1-дек.
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
12,04 млд
10,97 млд
12,44 млд
16,46 млд
Cost of goods sold
6,07 млд
4,91 млд
6,17 млд
-
Cost of revenue
6,07 млд
4,91 млд
6,17 млд
-
Research and development expenses
311,73 млн
236,94 млн
266,96 млн
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854,49 млн
853,67 млн
891,80 млн
-
Operating expense
1,38 млд
1,26 млд
1,22 млд
-
Total operating expenses
7,45 млд
6,17 млд
7,39 млд
-
Operating income
4,59 млд
4,80 млд
5,04 млд
-
Other non operating income
-470,36 млн
281,37 млн
-266,37 млн
-
EBT including unusual items
5,13 млд
6,75 млд
5,61 млд
-
EBT excluding unusual items
5,11 млд
6,95 млд
5,19 млд
-
Income tax expense
1,55 млд
1,09 млд
936,77 млн
-
Effective tax rate
30,19%
16,12%
16,71%
-
Other operating expenses
57,96 млн
25,84 млн
726,05 миң
-
Net income
3,51 млд
7,08 млд
4,65 млд
-
Net profit margin
29,18%
64,49%
37,40%
-
Earnings per share
1,24
1,42
1,57
2,20
Interest and investment income
1,21 млд
1,87 млд
439,82 млн
-
Interest expense
-226,71 млн
-
-30,95 млн
-
Net interest expenses
981,72 млн
1,87 млд
408,87 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 млд
5,61 млд
5,85 млд
-
Gain or loss from assets sale
-158,03 млн
218,40 млн
-
-
AI content may include mistakes. Learn more
Google колдонмолору